These results were consistent with the observations from the GEO database, demonstrating that SNAP25 expression at the protein level was significantly elevated in neuroendocrine cancer cells with a high malignancy profile compared to lung cancer cells with relatively lower malignancy (Figure 6A) (1.529 ± 0.041 vs 0.643 ± 0.044 vs 0.234 ± 0.091 vs 0.518 ± 0.074, H1299 vs A549 vs H520 vs BEAS-2B). The gene discussed is SNAP25; the disease is neuroendocrine carcinoma.